Central Nervous System (CNS) Therapeutics Market Expected to Reach $199.1 Billion by 2033—Allied Market Research

According to a new report published by Allied Market Research, titled, “Central Nervous System (CNS) Therapeutics Market," The central nervous system therapeutics market size was valued at $114.2 billion in 2023, and is estimated to reach $199.1 billion by 2033, growing at a CAGR of 5.7% from 2024 to 2033.

Central nervous system (CNS) therapeutics encompass a wide range of drugs designed to target and modulate the functioning of the central nervous system, which includes the brain and spinal cord. These pharmaceutical interventions are developed to address various neurological and psychiatric disorders, aiming to alleviate symptoms, slow down disease progression, or restore normal neural function. CNS therapeutics covers a broad range of neurological conditions such as anxiety disorders, mood disorders, psychotic disorders, neurodegenerative diseases, and epilepsy. The complex and intricate nature of the central nervous system poses unique challenges in drug development, requiring careful consideration of the blood-brain barrier, pharmacokinetics, and potential side effects. Despite these challenges, advancements in neuroscience continue to drive the discovery and refinement of CNS therapeutics, offering improved treatment outcomes in individuals affected by neurological and psychiatric disorders.

CNS therapeutics market trends that are driving the growth of the market include a rise in geriatric population and surge in research and development to develop new drugs for treatment of the central nervous system disorders. The rise in geriatric population stands as a pivotal driver for the growth of the central nervous system (CNS) therapeutics market. As individuals age, they become increasingly susceptible to a spectrum of neurological conditions, including Alzheimer's disease, Parkinson's disease, and various forms of dementia. For instance, according to a report by the World Health Organization, it was estimated that around 14% of adults aged 60 and over live with a mental disorder. 

The growing geriatric population worldwide, particularly in developed nations, has increased the demand for effective CNS therapeutics. The surge in demand can be attributed to the escalating need for innovative and targeted treatments that address the complexities of neurological disorders associated with aging. Thus, the rise in the geriatric population globally is expected to drive central nervous system therapeutics market growth.

Furthermore, surge in research and development to develop new drugs for the treatment of central nervous system disorders is expected to contribute significantly to the growth during central nervous system therapeutics market analysis. The surge in scientific exploration and pharmaceutical innovation is propelled by a growing understanding of the complex mechanisms governing the central nervous system and an increasing recognition of the unmet medical needs in neurological and psychiatric disorders.

Researchers are actively engaged in exploring novel drug targets, innovative therapeutic modalities, and advanced delivery systems to address the intricacies of CNS-related conditions. For instance, according to a report by National Library of Medicine, it was reported that in 2021, there was a total of 147 active clinical trials for Parkinson’s disease drug therapies. Thus, the surge in the research and development activities to develop new drugs for treatment of the central nervous system disorders is expected to drive the growth of the market. However, the high cost of the central nervous system (CNS) therapeutic drug stands out as a significant restraint for the growth during the CNS therapeutics market forecast. 
 
The CNS therapeutics market size is segmented based on disease type and region. By disease type, it is divided into neurovascular diseases, CNS trauma, mental health (anxiety disorders, epilepsy, mood disorders, psychotic disorders, others) neurodegenerative diseases (Alzheimer's disease, Parkinson’s disease, multiple sclerosis, Huntington's Disease, amyotrophic lateral sclerosis, others), infectious diseases, cancer, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

On the basis of disease type, the neurodegenerative diseases segment had the largest central nervous system therapeutics market share in 2023 and is expected to remain dominant during the forecast period owing to a surge in prevalence of neurodegenerative disorders globally. Neurodegenerative disorders, such as Alzheimer's disease, Parkinson’s disease, multiple sclerosis, Huntington's disease, Amyotrophic lateral sclerosis, have seen a rise in prevalence globally. The surge in the number of individuals suffering from neurodegenerative conditions resulted in increased demand for central nervous system therapeutics. Furthermore, the rise in geriatric population globally is expected to significantly contribute to the growth of the central nervous system (CNS) therapeutics market.

Region-wise, North America generated higher revenue in the central nervous system therapeutics industry in 2023, owing to strong presence of major key players such as Biogen Inc, Johnson and Johnson, Eli Lilly, and Company Inc. and Viatris Inc. In addition, the well-developed healthcare infrastructure and rise in prevalence of clinical depression and anxiety is expected to drive the growth of the central nervous system (CNS) therapeutics market in North America region. 
 
However, Asia-Pacific is expected to witness the highest CAGR during the forecast period owing to rise in geriatric population and improving healthcare infrastructure. Furthermore, the large patient base in the Asia-Pacific region is expected to contribute significantly to the growth of the central nervous system (CNS) therapeutics market in Asia-Pacific region.

Key Findings of the Study

• By disease type, the neurodegenerative diseases segment held the largest CNS therapeutics market share in the central nervous system therapeutics industry in 2023.
• Region-wise, North America held the largest market share in 2023. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period.